The North American systemic aspergillosis and systemic candidasis market is projected to reach US$ 3,352.62 million by 2027 from US$ 2,423.82 million in 2019; it is estimated to grow at a CAGR of 4.2% from 2020 to 2027.
The market growth is primarily attributed to rise in the prevalence of fungal diseases and hospital-acquired fungal infections. Moreover, the COVID-19 pandemic has highly affected countries in North America, further affecting the systemic aspergillosis and systemic candidasis market in the region.
Systemic aspergillosis and systemic candidasis are the types of fungal infections. In aspergillosis, molds majorly infect the respiratory tract of individuals. It is a severe pulmonary infection caused by the fungi belonging to the genus Aspergillus, which commonly affect people with weakened immune systems or lung diseases. Moreover, severe fungal infections may occur as comorbidities of AIDS, asthma, and cancer, as well as during hospital visits for organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal treatment; however, often delays or unavailability may lead to death, severe chronic illness, or blindness among patients. For instance, according to the journal of Fungi published in March 2017, HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), and asthma—along with the increasing incidence of cancers—are the primary drivers of fungal infections in both developed and developing countries globally. Furthermore, according to the estimates mentioned in the National Library of Medicine National Institutes of Health report published in October 2017, ~3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, ~10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis are reported annually across the world.
The systemic oral azoles segment accounted for the largest share of the North America systemic aspergillosis and systemic candidasis market, by type, in 2019, and it is further expected to register the highest CAGR during the forecast period. The growth of market for this segment is mainly attributed to advancements in systemic antifungal therapy. For instance, fluconazole has the most attractive pharmacologic (pharmacokinetics and pharmacodynamic) profile, including the capacity to produce high concentrations of active drug in cerebrospinal fluid (CSF) and urine.
A few major primary and secondary sources referred to while preparing this report on the North America systemic aspergillosis and systemic candidasis market are, US Food and Drug Administration, National Library of Medicine National Institutes of Health, and International Society for Human and Animal Mycology.